-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] With the announcement of the first quarter results of listed companies, the first quarter results have become the focus of investors
.
Traditional Chinese medicine also received much attention in the first quarter
.
In particular, the "14th Five-Year Plan" for the Development of Traditional Chinese Medicine has clarified the future development path of traditional Chinese medicine.
Driven by favorable policies, the traditional Chinese medicine industry is expected to usher in a new round of development opportunities
.
At present, a number of traditional Chinese medicine companies, including Kangenbei, Rhine Biotech, Zuoli Pharmaceutical, Pien Tze Huang, and Jiangzhong Pharmaceutical, have successively locked in their first quarterly performance growth expectations in advance
.
Among them, Conba recently released an announcement on the pre-increase in the first quarter of 2022.
It is expected that in the first quarter of 2022, Conba will achieve a year-on-year increase of 100% to 120% in net profit attributable to shareholders of listed companies, about 96 million to 105 million yuan; It is expected that the operating income in the first quarter of 2022 will increase slightly year-on-year to about 1.
596 billion yuan
.
The report shows that in the first quarter of 2022, Conba will continue to promote the two major projects of big brands and varieties and technological innovation-driven development, further optimize the business and product structure, and actively expand the business of self-care products including over-the-counter drugs and health consumer goods.
The market coverage of centralized purchasing products was increased, and the development of online new retail business was accelerated, and operating results continued to grow
.
According to the data, Kangenbei focuses on the main business of medicine and health, mainly engaged in the research and development, manufacturing, wholesale and distribution of medicines and general health products.
Functional health products are an important supporting product structure
.
Rhein Biotech also recently released a performance forecast for the first quarter of 2022.
It expects that the net profit attributable to shareholders of listed companies in the first quarter of 2022 will increase by 53.
25% to 81.
11% year-on-year, or about 33 million to 39 million yuan
.
As for the main reason for the change in performance, Rhine Bio said that the company's good year-on-year growth in operating performance was mainly due to the continued strong market demand for plant extraction.
According to preliminary calculations by the financial department, the company expects that the consolidated operating income in the first quarter of 2022 will increase by 30% year-on-year
.
In the first quarter, Rheinland continued to strengthen the market expansion of major varieties such as natural sweeteners and tea extracts, and further strengthened the company's cost control and improvement through continuous technological transformation, making the growth rate of net profit higher than that of operating income
.
According to the recent performance forecast released by Zuoli Pharmaceutical, in the first quarter of 2022, Zuoli Pharmaceutical's net profit increased by 52.
98%~62.
12% year-on-year, about 67 million yuan to 71 million yuan
.
Regarding the main reason for the change in performance, Zuoli Pharmaceutical stated that during the reporting period, the operating income of the company's main products Wuling Capsules, Bailing Tablets and Lingze Tablets all achieved rapid growth
.
During the reporting period, with the improvement of the company's profitability, the company's funds were more abundant, the loan scale was reduced, and the financial expenses were lower than the same period last year
.
During the reporting period, the impact of non-recurring gains and losses on the company's net profit was approximately RMB 900,000 to RMB 1.
1 million
.
Pien Tze Huang recently released the 2022 first quarter performance forecast, showing that the company expects a pre-increase in the first quarter of 2022, and the net profit attributable to shareholders of listed companies will increase by 20% to 24% year-on-year, to 678 million to 701 million yuan
.
The company made the above prediction based on the following reasons: the company strengthened market planning and expanded sales channels, and increased the sales of the core product Pien Tze Huang series
.
According to the data, in 2014, Pien Tze Huang began to implement the "one core, two wings" big health development strategy.
On the basis of consolidating the pharmaceutical manufacturing industry, it strengthened the two wings of cosmetics, daily chemical products, health care products, and health food, and at the same time expanded the pharmaceutical circulation industry as a supplement.
.
After several years of careful construction and hard work, the company has basically formed a multi-format gathering pattern in the health field, and the product structure has been optimized
.
In addition, Jiangzhong Pharmaceutical expects to achieve a year-on-year increase of about 15% in net profit attributable to shareholders of listed companies in the first quarter of 2022, to about 183 million yuan
.
For the main reason for the change in performance, Jiangzhong Pharmaceutical calls it the main business impact
.
In the first quarter of 2022, Jiangzhong Pharmaceutical will focus on the three major business priorities of "focusing on OTC, developing general health, and strengthening prescription drugs", strengthening brand building, expanding market layout, and maintaining a good momentum in product sales.
At the same time, the newly acquired company Jincheng Hays Pharmaceutical Co.
, Ltd.
's consolidated data, the company's operating performance achieved good growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Traditional Chinese medicine also received much attention in the first quarter
.
In particular, the "14th Five-Year Plan" for the Development of Traditional Chinese Medicine has clarified the future development path of traditional Chinese medicine.
Driven by favorable policies, the traditional Chinese medicine industry is expected to usher in a new round of development opportunities
.
At present, a number of traditional Chinese medicine companies, including Kangenbei, Rhine Biotech, Zuoli Pharmaceutical, Pien Tze Huang, and Jiangzhong Pharmaceutical, have successively locked in their first quarterly performance growth expectations in advance
.
Among them, Conba recently released an announcement on the pre-increase in the first quarter of 2022.
It is expected that in the first quarter of 2022, Conba will achieve a year-on-year increase of 100% to 120% in net profit attributable to shareholders of listed companies, about 96 million to 105 million yuan; It is expected that the operating income in the first quarter of 2022 will increase slightly year-on-year to about 1.
596 billion yuan
.
The report shows that in the first quarter of 2022, Conba will continue to promote the two major projects of big brands and varieties and technological innovation-driven development, further optimize the business and product structure, and actively expand the business of self-care products including over-the-counter drugs and health consumer goods.
The market coverage of centralized purchasing products was increased, and the development of online new retail business was accelerated, and operating results continued to grow
.
According to the data, Kangenbei focuses on the main business of medicine and health, mainly engaged in the research and development, manufacturing, wholesale and distribution of medicines and general health products.
Functional health products are an important supporting product structure
.
Rhein Biotech also recently released a performance forecast for the first quarter of 2022.
It expects that the net profit attributable to shareholders of listed companies in the first quarter of 2022 will increase by 53.
25% to 81.
11% year-on-year, or about 33 million to 39 million yuan
.
As for the main reason for the change in performance, Rhine Bio said that the company's good year-on-year growth in operating performance was mainly due to the continued strong market demand for plant extraction.
According to preliminary calculations by the financial department, the company expects that the consolidated operating income in the first quarter of 2022 will increase by 30% year-on-year
.
In the first quarter, Rheinland continued to strengthen the market expansion of major varieties such as natural sweeteners and tea extracts, and further strengthened the company's cost control and improvement through continuous technological transformation, making the growth rate of net profit higher than that of operating income
.
According to the recent performance forecast released by Zuoli Pharmaceutical, in the first quarter of 2022, Zuoli Pharmaceutical's net profit increased by 52.
98%~62.
12% year-on-year, about 67 million yuan to 71 million yuan
.
Regarding the main reason for the change in performance, Zuoli Pharmaceutical stated that during the reporting period, the operating income of the company's main products Wuling Capsules, Bailing Tablets and Lingze Tablets all achieved rapid growth
.
During the reporting period, with the improvement of the company's profitability, the company's funds were more abundant, the loan scale was reduced, and the financial expenses were lower than the same period last year
.
During the reporting period, the impact of non-recurring gains and losses on the company's net profit was approximately RMB 900,000 to RMB 1.
1 million
.
Pien Tze Huang recently released the 2022 first quarter performance forecast, showing that the company expects a pre-increase in the first quarter of 2022, and the net profit attributable to shareholders of listed companies will increase by 20% to 24% year-on-year, to 678 million to 701 million yuan
.
The company made the above prediction based on the following reasons: the company strengthened market planning and expanded sales channels, and increased the sales of the core product Pien Tze Huang series
.
According to the data, in 2014, Pien Tze Huang began to implement the "one core, two wings" big health development strategy.
On the basis of consolidating the pharmaceutical manufacturing industry, it strengthened the two wings of cosmetics, daily chemical products, health care products, and health food, and at the same time expanded the pharmaceutical circulation industry as a supplement.
.
After several years of careful construction and hard work, the company has basically formed a multi-format gathering pattern in the health field, and the product structure has been optimized
.
In addition, Jiangzhong Pharmaceutical expects to achieve a year-on-year increase of about 15% in net profit attributable to shareholders of listed companies in the first quarter of 2022, to about 183 million yuan
.
For the main reason for the change in performance, Jiangzhong Pharmaceutical calls it the main business impact
.
In the first quarter of 2022, Jiangzhong Pharmaceutical will focus on the three major business priorities of "focusing on OTC, developing general health, and strengthening prescription drugs", strengthening brand building, expanding market layout, and maintaining a good momentum in product sales.
At the same time, the newly acquired company Jincheng Hays Pharmaceutical Co.
, Ltd.
's consolidated data, the company's operating performance achieved good growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
